Cullinan Therapeutics stock is listed on Nasdaq, as reported by Benzinga.
10 reports, 2 independent
Updated 00:00
Still developing
- Reports
- 10
- Developments
- 2
- Repetition
- 80%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cullinan Therapeutics stock is listed on Nasdaq, as reported by Benzinga.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.TD Cowen and Wedbush raise ratings/targets for Cullinan Therapeutics.1 source
Cullinan Therapeutics begins trading on the Nasdaq stock exchange.1 source
Keep exploring
The entities involved
Related events
- BioMarin Pharmaceutical stock received updates on July 18, 2026, including a price target boost from Citigroup, reported by Benzinga.
- Acrivon Therapeutics, focusing on RAS-driven cancers, is listing shares on Nasdaq, with Jefferies providing investment research.
- Zentalis Pharmaceuticals, Inc. listed its shares on the Nasdaq stock exchange on July 24, 2026.
- BioMarin Pharmaceutical and CollPlant Biotechnologies were listed on Nasdaq and are being compared as healthcare companies.
- Mentari Therapeutics, Inc. was listed on the Nasdaq stock exchange on November 4, 2026.